Abstract
Alzheimers disease is a progressive neurodegenerative disease characterized by gradual and increasing loss of cognitive function and behavioral abnormalities. The formation of β-amyloid plaques and neurofibrillary tangles are recognized as the key pathologies of the disease. Changes in the levels of various key neurotransmitters has been noted in patients with Alzheimers disease and may represent the earliest biochemical casualty, preceding or signifying the onset of the disease. Over the last 20 years a number of approaches to the palliative treatment of Alzheimers disease have been scrutinized. The majority of effort has been focused on cognitive dysfunction, as this is the initial and key debilitating symptom of the disease. The identification and commercial development of the acetylcholinesterase inhibitors has, until recently, virtually dominated the field, and although efficacy has been demonstrated, the clinical results suggest alternate approaches are warranted. This review will highlight those palliative approaches that have focused on the improvement of learning and memory and not on the disease-modifying strategies of the β-amyloid, tau phosphorylation or other neurodegenerative hypotheses.
Keywords: neurotransmission, neurodegeneration, cognitive dysfunction, cognition, Alzheimer's disease, Palliative
Current Topics in Medicinal Chemistry
Title: Approaches to Palliative Therapies for Alzheimers Disease
Volume: 6 Issue: 6
Author(s): Albert J. Robichaud
Affiliation:
Keywords: neurotransmission, neurodegeneration, cognitive dysfunction, cognition, Alzheimer's disease, Palliative
Abstract: Alzheimers disease is a progressive neurodegenerative disease characterized by gradual and increasing loss of cognitive function and behavioral abnormalities. The formation of β-amyloid plaques and neurofibrillary tangles are recognized as the key pathologies of the disease. Changes in the levels of various key neurotransmitters has been noted in patients with Alzheimers disease and may represent the earliest biochemical casualty, preceding or signifying the onset of the disease. Over the last 20 years a number of approaches to the palliative treatment of Alzheimers disease have been scrutinized. The majority of effort has been focused on cognitive dysfunction, as this is the initial and key debilitating symptom of the disease. The identification and commercial development of the acetylcholinesterase inhibitors has, until recently, virtually dominated the field, and although efficacy has been demonstrated, the clinical results suggest alternate approaches are warranted. This review will highlight those palliative approaches that have focused on the improvement of learning and memory and not on the disease-modifying strategies of the β-amyloid, tau phosphorylation or other neurodegenerative hypotheses.
Export Options
About this article
Cite this article as:
Robichaud J. Albert, Approaches to Palliative Therapies for Alzheimers Disease, Current Topics in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/156802606776743039
DOI https://dx.doi.org/10.2174/156802606776743039 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acrylamide Induced Toxicity and the Propensity of Phytochemicals in Amelioration: A Review
Central Nervous System Agents in Medicinal Chemistry Phenothiazine: The Parent Molecule
Current Drug Targets Prolactin Protects Against the Methamphetamine-Induced Cerebral Vascular Toxicity
Current Neurovascular Research Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology
Current Pharmaceutical Design Recent Advances in the Treatment of Amyotrophic Lateral Sclerosis. Emphasis on Kynurenine Pathway Inhibitors
Central Nervous System Agents in Medicinal Chemistry The Delicate Equilibrium between Oxidants and Antioxidants in Brain Glioma
Current Neuropharmacology Is the Use of Proton-pump Inhibitors a Risk Factor for Alzheimer’s Disease? Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics Therapeutic Perspectives in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy
Current Topics in Medicinal Chemistry Ganglioside Mimicry as a Cause of Guillain-Barre Syndrome
CNS & Neurological Disorders - Drug Targets Adoptive Regulatory T-cell Therapy Attenuates Subarachnoid Hemor-rhage-induced Cerebral Inflammation by Suppressing TLR4/NF-B Signaling Pathway
Current Neurovascular Research Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects
Current Pharmaceutical Design Subject Index to Volume 4
Current Cancer Drug Targets Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine
Current Neuropharmacology subject Index To Volume 4
Combinatorial Chemistry & High Throughput Screening Polarization of Calcium Signaling and Fluid Secretion in Salivary Gland Cells
Current Medicinal Chemistry Genetic Analysis of CYP2D6 Polymorphism in Indian Populations and its Pharmacogenetic Implications
Current Pharmacogenomics and Personalized Medicine Development of Poly(lactide-co-glicolide) Nanoparticles Incorporating Morphine Hydrochloride to Prolong its Circulation in Blood
Current Pharmaceutical Design Phytochemical Informatics and Virtual Screening of Herbs Used in Chinese Medicine
Current Pharmaceutical Design